These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18474492)

  • 21. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
    Gripshover BM; Ribaudo H; Santana J; Gerber JG; Campbell TB; Hogg E; Jarocki B; Hammer SM; Kuritzkes DR;
    Antivir Ther; 2006; 11(5):619-23. PubMed ID: 16964830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
    Trottier B; Walmsley S; Reynes J; Piliero P; O'Hearn M; Nelson M; Montaner J; Lazzarin A; Lalezari J; Katlama C; Henry K; Cooper D; Clotet B; Arastéh K; Delfraissy JF; Stellbrink HJ; Lange J; Kuritzkes D; Eron JJ; Cohen C; Kinchelow T; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Bourdeau L; Natale C; Hughes F; Chung J; Guimaraes D; Drobnes C; Bader-Weder S; Demasi R; Smiley L; Salgo MP
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):413-21. PubMed ID: 16280695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
    Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
    Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
    J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
    Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
    HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
    Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
    HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
    Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS
    HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
    Clotet B; Capetti A; Soto-Ramirez LE; Gatell JM; Rowell L; Salgo M; Schapiro JM
    J Antimicrob Chemother; 2008 Dec; 62(6):1374-8. PubMed ID: 18782780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.
    Cossarini F; Galli L; Sagnelli C; Gianotti N; Hasson H; Clementi M; Soria A; Salpietro S; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):179-84. PubMed ID: 19352200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.